1. Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study
- Author
-
Matthew G. Garoufalis
- Subjects
Adult ,Foot Dermatoses ,medicine.medical_specialty ,Antifungal Agents ,Ciclopirox ,business.industry ,Administration, Topical ,Total dystrophic onychomycosis ,Nail lacquer ,General Medicine ,Efinaconazole Topical Solution ,Triazoles ,Dermatology ,Nail polish ,Coronavirus ,Podiatrist ,Treatment Outcome ,Onychomycosis ,Humans ,Medicine ,Female ,In patient ,business ,Efinaconazole ,medicine.drug - Abstract
Toenail onychomycosis is a common condition that is equally challenging for podiatrists and patients. This case study documents a 26-year-old woman with bilateral total dystrophic onychomycosis of at least 5 years’ duration. She had previously failed to respond to treatment with ciclopirox nail lacquer 8% and, despite hiding her condition with nail polish, was suffering from embarrassment, distress, and low self-esteem. At initial consultation, 100% of both great toenails was affected. After discussion of all treatment options, the patient opted for topical efinaconazole 10% solution, once daily for 48 weeks. Significant improvement was noted at the first (4-week) assessment period. This improvement was maintained through each subsequent virtual consultation, and complete cure was seen at a 30-week follow-up visit. To the author’s knowledge, this is the first published report on the use of efinaconazole in total dystrophic onychomycosis. It suggests that the product may be effective in patients with even the most severe and treatment-recalcitrant disease, who are unwilling or unable to tolerate systemic antifungal therapy.
- Published
- 2022
- Full Text
- View/download PDF